TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
AVNS

Avanos Medical Inc

Healthcare · Medical Devices

25.00$ +0.0% vs. previous close Closing price · As of: Jul 24, 2026

Investor relations

Report Dates

Investor relations overview for Avanos Medical Inc (AVNS): report dates, earnings surprises, earnings call transcripts and the latest headlines. The next report is scheduled for 08/04/2026.

Next report 08/04/2026
Last report 05/05/2026
Earnings surprise by quarter (%)
Q2 23 · -25.0 % 23 Q3 23 · 7.1 % 23 Q4 23 · -13.5 % 23 Q1 24 · -9.5 % 24 Q2 24 · 17.2 % 24 Q3 24 · 2.9 % 24 Q4 24 · 8.4 % 24 Q1 25 · 44.4 % 25 Q2 25 · 13.3 % 25 Q3 25 · 37.5 % 25 Q4 25 · 16.0 % 25 Q1 26 · 57.1 % 26

EPS estimate beaten

Full history 35 of 46 quarters (76%)
Last 16 quarters 12 of 16 quarters (75%)

Earnings Call Transcripts

Search all transcripts →

No transcripts yet — they will show up here automatically after the next earnings call.

News on This Stock

  • 07/30/2026 AVANOS MEDICAL, INC. (AVNS): Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Material Modifications to Rights of Security Holders; Changes in Control of Registrant; Departure of Directors · sec.gov Open ↗
  • 07/22/2026 AVANOS MEDICAL, INC. (AVNS): Submission of Matters to a Vote of Security Holders; Regulation FD Disclosure; Financial Statements and Exhibits · sec.gov Open ↗
  • 07/14/2026 AVANOS MEDICAL, INC. (AVNS): Other Events; Financial Statements and Exhibits · sec.gov Open ↗

Automatically matched wire and portal stories; external links open the original source.

Data as of: July 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Transcripts: transcript archive

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?